Page 354 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 354

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
                                        surveillance/ watchful waiting/other observational management strategies (continued)

                                        Center, Country       Eligibility criteria                 Followup or monitoring protocol                       Triggers for intervention/        Definition of
                                        [PMID]                                                                                                             active therapy                    progression
                                        Enrollment year
                                                                                                                   st
                                        Kagawa Medical        Japanese patients  PSA doubling time based on 1  PSA >1 mo after biopsy. ≥3                NR                                NR
                                        Univ., Japan 153        with                  values at intervals ≥1 mo apart for >6 mo. Exponential slope
                                        [10765093]              nonpalpable           fitted by regression.
                                                                prostate cancer,
                                        1990-1998               detected by
                                                                elevated PSA.
                                                                Diagnosed
                                                                histopathologic
                                                                ally by TRUS-
                                                                guided six
                                                                sextant biopsy:
                                                                (1) Gleason
                                                                score ≤6; (2)
                                                                1-2 positive
                                                                cores per 6
                                                                sextant cores;
                                                                and (3) ≤50%
                                                                involvement of
                                                                any positive
                                                                core



































                                                                                                                        C-95
   349   350   351   352   353   354   355   356   357   358   359